Global COVID-19 cases near 250 million as Delta surge eases

Over the last three months, the daily average number of cases has fallen by 36%, according to a Reuters analysis.

Reuters
November 08, 2021 / 08:28 AM IST

Representative image (Image: AP)

Worldwide cases due to COVID-19 were approaching 250 million on Sunday as the surge from the Delta variant eases and more normal trade and tourism resume, although some countries in eastern Europe are experiencing record outbreaks.

Over the last three months, the daily average number of cases has fallen by 36%, according to a Reuters analysis.

Even though the spread has slowed, the virus is still infecting 50 million people every 90 days due to the highly transmissible Delta variant, the analysis showed. It took nearly a year to record the first 50 million COVID cases.

Health experts are optimistic that many nations have put the worst of the pandemic behind them thanks to vaccines and natural exposure, although they caution that colder weather and upcoming holiday gatherings could increase cases.

"We think between now and the end of 2022, this is the point where we get control over this virus … where we can significantly reduce severe disease and death," Maria Van Kerkhove, an epidemiologist leading the World Health Organisation, told Reuters.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

In addition to vaccines, doctors now have better treatments. Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics called molnupiravir. Studies showed it could halve the chances of dying or being hospitalised for those most at risk of developing severe COVID-19 when given early in the illness.

Infections are still rising in 55 out of 240 countries, with Russia, Ukraine and Greece at or near record levels of reported cases since the pandemic started two years ago, according to a Reuters analysis.

Eastern Europe has among the lowest vaccination rates in the region. More than half of all new infections reported worldwide were from countries in Europe, with a million new infections about every four days, according to the analysis.

Several Russian regions said this week they could impose additional restrictions or extend a workplace shutdown to fight a surge in COVID-19 cases as the country witnesses record deaths due to the disease.

More than half of the world’s population has yet to receive a single dose of a COVID-19 vaccine, according to Our World in Data. Less than 5% of people in low-income countries have received at least one dose.

The World Health Organization (WHO) and other aid groups last month appealed to leaders of the world’s 20 biggest economies to fund a $23.4 billion plan to bring COVID-19 vaccines, tests, and drugs to poorer countries in the next 12 months.

"Vaccine inequity remains the biggest barrier to reaching our coverage targets," PAHO Assistant Director Jarbas Barbosa, urging authorities to prioritize the elderly, frontline workers, and people with pre-existing conditions, to protect them from overburdening the healthcare system.
Reuters
Tags: #coronavirus #Covid-19 #Global COVID-19 #World News
first published: Nov 8, 2021 08:29 am